PIK3CA-associated pulmonary adenocarcinoma
Friday 28 June 2013
Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K).
PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein have been associated with tumorigenesis and treatment resistance in various malignancies.
PIK3CA mutations occur in lung adenocarcinomas, usually concurrently with EGFR, KRAS, and ALK.
The impact of PIK3CA mutations on the efficacy of targeted therapies such as erlotinib and crizotinib is unknown.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG. Mol Cancer Ther. 2012 Feb;11(2):485-91. doi:10.1158/1535-7163.MCT-11-0692 . PMID: #22135231#